Does the addition of lamotrigine to risperidone improve psychotic symptoms and cognitive impairments in chronic schizophrenia?

Therapy

Volumn 2, Issue 3, 2005, Pages 399-406

  Akhondzadeh, Shahin ^a   Mackinejad, K ^b   Ahmadi Abhari, S A ^b   Alem, Z M ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Attention; Chronic schizophrenia; Cognition; Lamotrigine; Risperidone

Indexed keywords

BIPERIDEN; GLUTAMIC ACID; KETAMINE; LAMOTRIGINE; MOOD STABILIZER; PLACEBO; RISPERIDONE;

ADJUVANT THERAPY; ANALYTICAL ERROR; ARTICLE; ATAXIA; ATTENTION; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HAIR LOSS; HOSPITAL PATIENT; HUMAN; LEARNING DISORDER; MEMORY DISORDER; MENTAL DISEASE; MENTAL PATIENT; NAUSEA; NEUROTRANSMITTER RELEASE; PATIENT SELECTION; PROGNOSIS; PRURITUS; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOMATOLOGY; VISUAL IMPAIRMENT; VOMITING;

EID: 20344379434     PISSN: 14750708     EISSN: None     Source Type: Journal    
DOI: 10.1586/14750708.2.3.399     Document Type: Article

References (21)

1. Jablensky A, Sartorius N, Ernberg G. Schizophrenia: manifestation, incidence and course in different cultures. World Health Organization 10-country study. Psychol. Med. 20(Suppl.), 1-97 (1991).
2. Mohammadi MR, Akhondzadeh S, Schizophrenia: Etiology and pharmacotherapy. Drugs 4, 1167-1172 (2001).
3. Green MF. What are the functional consequence of neurocognitive deficits in schizophrenia? Am. J. Psychiat. 153, 321-330 (1996).
4. Sharma T, Harvey PD. Cognitive enhancement as a treatment strategy in schizophrenia. In: Schizophrenia and Cognition. Sharma T, Harvey T (Eds). Oxford University Press, Oxford, UK (2001).
5. Keek RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schziophr. Bull. 25, 291-222 (1999).
6. Purdon SE. Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophr. Res. 35, 51-60 (1999).
7. Abramczyk RR, Jordan DE, Hegel M. "Reverse" Stroop effect in the performance of schizophrenics. Percept. Mot. Skills 56, 99-108 (1983).
8. Liddle PF, Morris DL. Schizophrenic syndromes and frontal lobe performance. Br. J. Psychiat. 158, 340-345 (1991).
9. Idris NF, Repeto O, Neill JC, Large CH. Investigation of the effects of lamotrigine and clozapine in improving reversal learning impairments induced by acute phencyclidine and D: amphetamine in the rat. Psychopharmacology 12, 15-22 (2005).
10. Dursan SM, MaIntosh D, Milliken H. Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch. Gen. Psychiat. 56, 950 (1999).
11. Dursun SM, Deakin JF. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J. Psychopharmacology 15, 297-301 (2001).
12. Saba G, Dumortrier G, Kalalou K et al. Lamotrigine-clozapine combination in refractory schizophrenia: three cases. J. Neuropsychiat. Clin. Neurosci. 14, 86 (2002).
13. Anand A, Charney DS, Oren DA et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamategic effects of N-methyl-D-aspartate receptor antagonists. Arch. Gen. Psychiat. 57, 270-276 (2000).
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th Edition). American Psychiatric Press, Washington, DC, USA (1994).
15. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale for schizophrenia. Schizophrenia Bull. 13, 261-276 (1987).
16. Chouinard G, Ross-Chouinard A, Annables L, Jones BD. Extrapyramidal symptoms rating scale. Can. J. Neurol. Sci. 7, 233 (1980) (Abstract).
17. Golden CJ. Stroop color and word test. In: Manual for Clinical and Experimental Uses. Stoelting, IL, USA, 30150 (1978).
18. Mohamed S, Paulsen JS, O'Leary D, Arndt S, Andreasen N. Generalized cognitive deficit in schizophrenia: a study of first-episode patients. Arch. Gen. Psychiat. 56, 749-754 (1999).
19. Tiihonen J, Hallikainen T, Ryynanen OP et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol. Psychiat. 54, 1241-1248 (2003).
20. Kremer I, Vass A, Gorelik I et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol. Psychiat. 56, 441-446 (2004).
21. Akhondzadeh S. The glutamate hypothesis of schizophrenia. J. Clin. Pharm. Therapeut. 23, 243-246 (1998).